Anatomical factors and device integration require modified diagnostic workflows to manage complicated urinary tract ...

New research from the NEXIS trial provides valuable insight into recovery after critical illness. While an enhanced ...

Studies suggesting a link between COVID-19 vaccination and improved outcomes with ICIs may be driven by pandemic-era confounding and selection bias.

SER-155 is an oral live biotherapeutic being investigated to treat disruptive conditions of the gastrointestinal tract. In a ...

New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting highlights a ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...

Immune checkpoint inhibitors (ICIs) have transformed oncology, enabling patients with previously untreatable malignancies to achieve durable responses. However, as the use of agents such as ...

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses ...

The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

Background Sociodemographic inequalities impact patients with non-small cell lung cancer (NSCLC). Advances in novel ...

The between-group [those treated with ICIs vs those not treated with ICIs] difference in the change in PMD was significant (adjusted P =.001) but the difference in SMI was not (P =.38). Psoas muscle ...